BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 25636377)

  • 1. Mobilization of hematopoietic stem cells with lenograstim in healthy donors: efficacy and safety analysis according to donor age.
    Martino M; Bonizzoni E; Moscato T; Recchia AG; Fedele R; Gallo GA; Console G; Messina G; Morabito F
    Biol Blood Marrow Transplant; 2015 May; 21(5):881-8. PubMed ID: 25636377
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short and long-term safety of lenograstim administration in healthy peripheral haematopoietic progenitor cell donors: a single centre experience.
    Martino M; Console G; Dattola A; Callea I; Messina G; Moscato T; Massara E; Irrera G; Fedele R; Gervasi A; Bresolin G; Iacopino P
    Bone Marrow Transplant; 2009 Aug; 44(3):163-8. PubMed ID: 19182833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
    Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
    Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Volunteer unrelated donor experience after administration of filgrastim and apheresis for the collection of haemopoietic stem cells: the Australian perspective.
    Gordon SV; Nivison-Smith I; Szer J; Chapman JR
    Intern Med J; 2013 Nov; 43(11):1183-90. PubMed ID: 24007325
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of healthy volunteer stem cell mobilization with filgrastim G-CSF and mobilized stem cell apheresis: results of a prospective longitudinal 5-year follow-up study.
    Mueller MM; Bialleck H; Bomke B; Brauninger S; Varga C; Seidl C; Seifried E; Tonn T; Bonig H
    Vox Sang; 2013 Jan; 104(1):46-54. PubMed ID: 22827736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mobilization of hematopoietic progenitor stem cells in allogeneic setting with lenograstim by subcutaneous injection, in daily or twice-daily dosing: a single-center prospective study with historical control.
    Martino M; Moscato T; Barillà S; Dattola A; Pontari A; Fedele R; Furlò G; Marzia Stilo C; Alberto Gallo G; Tripepi G
    Transfusion; 2015 Aug; 55(8):2032-8. PubMed ID: 25857853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biosimilar G-CSF versus filgrastim and lenograstim in healthy unrelated volunteer hematopoietic stem cell donors.
    Farhan R; Urbanowska E; Zborowska H; Król M; Król M; Torosian T; Piotrowska I; Bogusz K; Skwierawska K; Wiktor-Jędrzejczak W; Snarski E
    Ann Hematol; 2017 Oct; 96(10):1735-1739. PubMed ID: 28801752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral blood stem cell yield in 400 normal donors mobilised with granulocyte colony-stimulating factor (G-CSF): impact of age, sex, donor weight and type of G-CSF used.
    Ings SJ; Balsa C; Leverett D; Mackinnon S; Linch DC; Watts MJ
    Br J Haematol; 2006 Sep; 134(5):517-25. PubMed ID: 17018030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the efficacy and safety of original filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) in CD34(+) peripheral hematopoietic stem cell mobilization procedures for allogeneic hematopoietic stem cell transplant donors.
    Sivgin S; Karakus E; Keklik M; Zararsiz G; Solmaz M; Kaynar L; Eser B; Cetin M; Unal A
    Transfus Apher Sci; 2016 Jun; 54(3):410-5. PubMed ID: 27052362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of peripheral blood stem cell collection in elderly donors; does age interfere?
    Lysák D; Kořístek Z; Gašová Z; Skoumalová I; Jindra P
    J Clin Apher; 2011; 26(1):9-16. PubMed ID: 21312254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors predicting peripheral blood progenitor cell collection from pediatric donors for allogeneic transplantation.
    Díaz MA; Sevilla J; de la Rubia J; Verdeguer A; Espigado I; Vicent MG; Pascual MJ; Zamora C; Arrieta R; Serrano D; del Cañizo C; Arbona C; de Arriba F; Bargay J; Brunet S; Sanz MA
    Haematologica; 2003 Aug; 88(8):919-22. PubMed ID: 12935980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Collection of peripheral blood progenitor cells on Day 4 is feasible and effective while reducing granulocyte-colony-stimulating factor exposure to healthy donors.
    Flommersfeld S; Sohlbach K; Jaques G; Bein G; Hoffmann J; Kostrewa P; Sachs UJ
    Transfusion; 2015 Jun; 55(6):1269-74. PubMed ID: 25647638
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical study of single-dose G-CSF in mobilization and reconstruction of allogeneic peripheral blood stem cell transplantation].
    Tian H; Zhou SY
    Ai Zheng; 2003 Dec; 22(12):1325-9. PubMed ID: 14693061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
    Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
    Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Collection of hematopoietic progenitor cells from healthy donors].
    Bojanić I; Cepulić BG; Mazić S
    Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of hematopoietic stem cell collection from mobilized peripheral blood in unrelated volunteers: 12 years of single-center experience in 3928 donors.
    Hölig K; Kramer M; Kroschinsky F; Bornhäuser M; Mengling T; Schmidt AH; Rutt C; Ehninger G
    Blood; 2009 Oct; 114(18):3757-63. PubMed ID: 19666868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GM-CSF-based mobilization effect in normal healthy donors for allogeneic peripheral blood stem cell transplantation.
    Sohn SK; Kim JG; Seo KW; Chae YS; Jung JT; Suh JS; Lee KB
    Bone Marrow Transplant; 2002 Jul; 30(2):81-6. PubMed ID: 12132046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stem cell mobilisation with 16 microg/kg vs 10 microg/kg of G-CSF for allogeneic transplantation in healthy donors.
    Kröger N; Renges H; Sonnenberg S; Krüger W; Gutensohn K; Dielschneider T; Cortes-Dericks L; Zander AR
    Bone Marrow Transplant; 2002 May; 29(9):727-30. PubMed ID: 12040468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of hematopoietic progenitor cell donor characteristics predicting successful mobilization: results of an Italian multicenter study.
    Bertani G; Santoleri L; Martino M; Fedele R; Moscato T; Marenco P; Grillo G; Zucchetti E; Lotesoriere I; Lando G; Cesana C; Cairoli R; Rossini S
    Transfusion; 2014 Aug; 54(8):2028-33. PubMed ID: 24588265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive factors that affect the mobilization of CD34(+) cells in healthy donors treated with recombinant granulocyte colony-stimulating factor (G-CSF).
    Martino M; Callea I; Condemi A; Dattola A; Irrera G; Marcuccio D; Messina G; Pontari A; Pucci G; Console G; Lacopino P
    J Clin Apher; 2006 Oct; 21(3):169-75. PubMed ID: 16532489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.